FDA grants priority review to belimumab

Friday 20 August 2010

The US Food and Drug Administration has granted priority review status to belimumab, a potential treatment for systemic lupus erythematosus, according to the drug’s co-developers, GlaxoSmithKline Plc and Human Genome Sciences Inc.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States